MYD88 and neoplasm: Research on an H22 HCC mouse model highlighted the robust anti-tumor potential of salvianolic acid B. The findings revealed that salvianolic acid B not only curbed tumor growth but also mitigated inflammation-related immune activity by regulating the TLR4/MyD88/NF-κB pathway [46].